NAD+

This entry summarises published research. It is not guidance on use, and research-grade material is not for human or veterinary use.

What it is

NAD+ is a coenzyme involved in redox reactions and in many signalling enzymes. It is not a peptide. It appears in research-peptide catalogues because the same buyers often look for it, and vendors sell it as a lyophilised powder.

What has been studied

Reviews cover NAD+ metabolism and how cellular NAD+ levels change with age. Most of the in vivo work they summarise uses precursor molecules that cells convert into NAD+, rather than NAD+ itself. Keep that distinction in mind when a listing cites this literature.

Reading supplier listings

A partner certificate we reviewed reports NAD+ “by content”, 603.54 mg in a 500 mg vial, rather than as a purity percentage. A measured content above the label is not unusual. It reflects what was weighed into the vial and how the laboratory measured it.

Regulatory status

A ubiquitous metabolite rather than a novel compound. Much research uses NAD+ precursors rather than NAD+ itself. Research-grade NAD+ from peptide vendors is a laboratory reagent.

Known limitations of the evidence

• Much of the in vivo evidence concerns NAD+ precursors, not NAD+ itself.
• Certificates for NAD+ often report measured content rather than a peptide-style purity figure.

References

1. Review Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science, 2015 (opens an external site in a new tab) link checked 2 Oct 2026
2. Review Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab, 2018 (opens an external site in a new tab) link checked 2 Oct 2026
3. Review Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol, 2021 (opens an external site in a new tab) link checked 2 Oct 2026
4. Chemical database NAD+ — PubChem CID 5892 (opens an external site in a new tab) link checked 2 Oct 2026